BACKGROUND: There are limited data on treatment-related anemia in Asian HIV-infected children. METHODS: Data from Asian HIV-infected children aged <18 years on first-line highly active antiretroviral therapy (HAART) were used. Children who had pre-existing severe anemia at baseline were excluded. Anemia was graded using the United States Division of AIDS (DAIDS) 2004 table. Potential risk factors for severe anemia were assessed by logistic regression. RESULTS: Data from 1648 children (51.9% female, 62.8% World Health Organization (WHO) stage 3/4) were analyzed. Median (interquartile range) age was 6.8 (3.7-9.6) years, CD4% was 9 (3-16)%, and plasma HIV-RNA was 5.2 (4.7-5.6) log10 copies/ml at HAART initiation in those with available testing. The most common regimens were stavudine/lamivudine/nevirapine (42%) and zidovudine/lamivudine/nevirapine (25%). Severe anemia was identified in 47 (2.9%) children after a median time of 6 months after HAART initiation, with an incidence rate of 5.4 per 100 child-years. Mild anemia or moderate anemia at baseline (p = 0.024 and p = 0.005, respectively), previous or current use of zidovudine (p < 0.0001 and p = 0.013, respectively), and male sex (p = 0.008) were associated with severe anemia. Higher weight-for-age z-score (p = 0.004) was protective. CONCLUSIONS: The incidence of severe anemia in Asian HIV-infected children after HAART initiation was low and mainly occurred during the first few months after HAART initiation. Mild to moderate anemia at baseline and using zidovudine were independent risk factors for the development of severe anemia.
BACKGROUND: There are limited data on treatment-related anemia in Asian HIV-infectedchildren. METHODS: Data from Asian HIV-infectedchildren aged <18 years on first-line highly active antiretroviral therapy (HAART) were used. Children who had pre-existing severe anemia at baseline were excluded. Anemia was graded using the United States Division of AIDS (DAIDS) 2004 table. Potential risk factors for severe anemia were assessed by logistic regression. RESULTS: Data from 1648 children (51.9% female, 62.8% World Health Organization (WHO) stage 3/4) were analyzed. Median (interquartile range) age was 6.8 (3.7-9.6) years, CD4% was 9 (3-16)%, and plasma HIV-RNA was 5.2 (4.7-5.6) log10 copies/ml at HAART initiation in those with available testing. The most common regimens were stavudine/lamivudine/nevirapine (42%) and zidovudine/lamivudine/nevirapine (25%). Severe anemia was identified in 47 (2.9%) children after a median time of 6 months after HAART initiation, with an incidence rate of 5.4 per 100 child-years. Mild anemia or moderate anemia at baseline (p = 0.024 and p = 0.005, respectively), previous or current use of zidovudine (p < 0.0001 and p = 0.013, respectively), and male sex (p = 0.008) were associated with severe anemia. Higher weight-for-age z-score (p = 0.004) was protective. CONCLUSIONS: The incidence of severe anemia in Asian HIV-infectedchildren after HAART initiation was low and mainly occurred during the first few months after HAART initiation. Mild to moderate anemia at baseline and using zidovudine were independent risk factors for the development of severe anemia.
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: Job C J Calis; Michaël Boele van Hensbroek; Rob J de Haan; Peter Moons; Bernard J Brabin; Imelda Bates Journal: AIDS Date: 2008-06-19 Impact factor: 4.177
Authors: Paul A Volberding; Alexandra M Levine; Douglas Dieterich; Donna Mildvan; Ronald Mitsuyasu; Michael Saag Journal: Clin Infect Dis Date: 2004-04-27 Impact factor: 9.079
Authors: Francis Ssali; Wolfgang Stöhr; Paula Munderi; Andrew Reid; A Sarah Walker; Diana M Gibb; Peter Mugyenyi; Cissy Kityo; Heiner Grosskurth; James Hakim; Helen Byakwaga; Elly Katabira; Janet H Darbyshire; Charles F Gilks Journal: Antivir Ther Date: 2006
Authors: Catherine G Sutcliffe; Janneke H van Dijk; Bornface Munsanje; Francis Hamangaba; Pamela Siniwymaanzi; Philip E Thuma; William J Moss Journal: PLoS One Date: 2011-12-21 Impact factor: 3.240
Authors: Pagakrong Lumbiganon; Pope Kosalaraksa; Torsak Bunupuradah; David Boettiger; Vonthanak Saphonn; Khanh H Truong; Nia Kurniati; Rawiwan Hansudewechakul; Viet C Do; Tavitiya Sudjaritruk; Nagalingeswaran Kumarasamy; Nantakar Kongstan; Nik K N Yusoff; Lam V Nguyen; Dewi K Wati; Kamarul Razali; Annette H Sohn; Azar Kariminia Journal: Asian Biomed (Res Rev News) Date: 2016-06
Authors: Marlon Liyanage; Mina Nikanjam; Lynn McFadyen; Manoli Vourvahis; Luise Rogg; John Moye; Ellen G Chadwick; Patrick Jean-Philippe; Mark Mirochnick; Kyle Whitson; Sarah Bradford; Edmund V Capparelli; Brookie M Best Journal: Pediatr Infect Dis J Date: 2022-08-09 Impact factor: 3.806